Mission Therapeutics concludes clinical assessment for lead DUB inhibitor
Safety, tolerability and pharmacokinetic endpoints for MTX652 have been successfully met
Read More
Tag: DUB
Almac links with MSD in research collaboration
Almac and MSD will initially work together in a two-year joint research programme
Read More
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
